Back
Clinuvel Pharmaceuticals Quote, Financials, Valuation and Earnings
DeFi Coin Triggers All "Buy" Signals And Could Break Out Soon
Discover our top DeFi pick for potentially massive gains now (before it's too late).
Sell
38
CLVLY
Clinuvel Pharmaceuticals
Last Price:
9.80
Seasonality Move:
2.81%
7 Day Trial
ALL ACCESS PASS
$
7
20 Most Hated Stocks on Wall Street
Click here to see the full list and protect yourself before it's too late.Clinuvel Pharmaceuticals Price Quote
$9.80
-0.17 (-1.74%)
(Updated: May 2, 2024 at 5:00 PM ET)
Clinuvel Pharmaceuticals Key Stats
Sell
38
Clinuvel Pharmaceuticals (CLVLY)
is a Sell
Day range:
$9.97 - $9.97
52-week range:
$8.54 - $13.92
Dividend yield:
0.33%
P/E ratio:
25.08
P/S ratio:
9.82
P/B ratio:
4.11%
Volume:
514
Avg. volume:
3K
1-year change:
-26.4%
Market cap:
$500M
Revenue:
$52.7M
EPS:
$0.38
How Much Does Clinuvel Pharmaceuticals Make?
-
How Much Are Clinuvel Pharmaceuticals's Sales Annually?
CLVLY Revenues are $52.7M -
How Much Profit Does Clinuvel Pharmaceuticals's Make A Year?
CLVLY net income is $20.6M
Is Clinuvel Pharmaceuticals Growing As A Company?
Data Unavailable
Clinuvel Pharmaceuticals Stock Price Performance
-
Did Clinuvel Pharmaceuticals Stock Go Up Last Month?
Clinuvel Pharmaceuticals share price went up by 4.44% last month -
Did CLVLY's Share Price Rise Over The Last Year?
CLVLY share price fell by -26.4% over the past 1 year
What Is Clinuvel Pharmaceuticals 52-Week High & Low?
-
What Is Clinuvel Pharmaceuticals’s 52-Week High Share Price?
Clinuvel Pharmaceuticals has traded as high as $13.92 over the past 52 weeks -
What Is Clinuvel Pharmaceuticals’s 52-Week Low Share Price?
Clinuvel Pharmaceuticals has traded as low as $8.54 over the past 52 weeks
Clinuvel Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Clinuvel Pharmaceuticals?
-
How Much Debt Does Clinuvel Pharmaceuticals Have?
Total long term debt quarterly is $728.2K -
How Much Cash Does Clinuvel Pharmaceuticals Have?
Cash and short term investments quarterly total is $118.9M -
What Is Clinuvel Pharmaceuticals’s Book Value Per Share?
Book value per share is 2.43
Is Clinuvel Pharmaceuticals Cash Flow Positive?
Data Unavailable
Clinuvel Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
CLVLY return on invested capital is 18.31% -
What Is Clinuvel Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 15.69% -
What Is CLVLY Return On Equity?
ROE is a measure of profitability and is 18.4%
Clinuvel Pharmaceuticals Earnings Date & Stock Price
-
What Is Clinuvel Pharmaceuticals's Stock Price Today?
A single share of CLVLY can be purchased today for 9.97 -
What Is Clinuvel Pharmaceuticals’s Stock Symbol?
Clinuvel Pharmaceuticals trades on the otcm under the ticker symbol: CLVLY -
When Is Clinuvel Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Clinuvel Pharmaceuticals is scheduled on May 2, 2024 -
When Is CLVLY's next ex-dividend date?
Clinuvel Pharmaceuticals's next ex-dividend date is September 7, 2023 -
How To Buy Clinuvel Pharmaceuticals Stock?
You can buy Clinuvel Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Clinuvel Pharmaceuticals Competitors
-
Who Are Clinuvel Pharmaceuticals's Competitors?
Below is a list of companies who compete with Clinuvel Pharmaceuticals or are related in some way:
Clinuvel Pharmaceuticals Dividend Yield
-
What Is CLVLY Dividend Yield?
Clinuvel Pharmaceuticals’s dividend yield currently is 0.33% -
What Is Clinuvel Pharmaceuticals’s Payout Ratio?
Clinuvel Pharmaceuticals’s payout ratio is 8.06% -
When Did Clinuvel Pharmaceuticals Last Pay A Dividend?
The latest dividend pay date is May 2, 2024 -
What Is Clinuvel Pharmaceuticals’s Dividend Per Share?
Clinuvel Pharmaceuticals pays a dividend of $0.00 per share
Clinuvel Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 0% |
| Revenue: | 0% | 0% |
Analyst Recommendations
| Buy Recommendations: | 0 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 0.00 |
| Downside from Last Price: | -100% |
Major Shareholders
Data Unavailable